Detecting a Genomic UIP Pattern to Improve ILD Diagnosis and Prognosis with the Envisia Classifier
In this Bronchoscopy Blitz segment, Interventional Pulmonologist, Dr. Fayez Kheir shares the latest data on the role of Envisia in the diagnosis and prognosis of ILD patients including application of the test in combination with cryobiopsy.
61 year old female with worsening lung function
Hear ILD pulmonologist experts discuss the diagnostic workup for this patient including how the Envisia Genomic Classifier impacted clinical decision making.
72 year old active male with exertional dyspnea
Hear ILD pulmonologist experts discuss the diagnostic workup for this patient including how the Envisia Genomic Classifier impacted clinical decision making.
80 year old male with progressive shortness of breath
Hear ILD pulmonologist experts discuss the diagnostic workup for this patient including how the Envisia Genomic Classifier impacted clinical decision making.
Employment of the Envisia Genomic Classifier in Conjunction with Cryobiopsy in Patient with Undiagnosed Interstitial Lung Disease
Retrospective analysis of patients in a multi-center study assessing change in management strategy following Envisia and cryobiopsy and the association between Envisia UIP classification and disease progression. Results showed combining Envisia with Cryobiopsy demonstrated meaningful impact on therapeutic strategy for ILD patients. Envisia positive patients who were not prescribed antifibrotics were twice as likely to progress compared to Envisia negative patients.
Improving ILD Diagnosis and Predicting Clinical Progression with the Envisia Genomic Classifier
Speakers discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data is presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic ILD.
Inter-reader Variability Between Two Expert Thoracic Radiologists in the Interpretation of HRCT Findings in Patients With Interstitial Lung Disease
HRCTs were independently read by two expert thoracic radiologists in the BRAVE study in 74 patient ILD cases. Inter-reader variability was notable when interpreting HRCT findings. This data highlights the need for multi-disciplinary approaches and additional testing modalities, such as a genomic classifier or histopathology, to establish a confident clinical diagnosis in these patients rather than relying on HRCT alone.
Impact of Genomic Classifier in Patients with Undiagnosed ILD
In an independent, multi-center study, researchers retrospectively analyzed data for 98 patients with ILD that underwent a clinically indicated bronchoscopy with cryobiopsy and the Envisia Genomic Classifier to assess change in management. The authors concluded that adding Envisia to cryobiopsy demonstrated a meaningful impact on therapeutic intervention with a 76% change in management strategy with more patients being started on antifibrotic therapy following a positive Envisia result.
Genomic Classifier for UIP Predicts Progression in Fibrotic Lung Disease Across a Range of Clinical Diagnoses
Findings from a retrospective analysis of 135 patients from the BRAVE trial examined the impact of an Envisia Genomic Classifier result on FVC progression at 12 months. The study found that Envisia may serve as a biomarker of progression across a range of ILD patients and could prompt earlier treatment intervention to slow progression.
A positive Envisia Genomic Classifier result may predict clinical progression in fibrotic interstitial lung disease
The Envisia classifier positive result may serve as a biomarker for FVC by identifying the genomic signature of UIP in patients without definite UIP on CT. Results for the study showed that patients with an Envisia positive result show a greater decline in FVC over time compared to Envisia negative patients. The Envisia classifier could have utility in identifying patients with IPF and non-IPF progressive pulmonary fibrosis and underlying UIP earlier in their disease, allowing for aggressive therapy before significant, irreversible FVC loss.